Literature DB >> 26221402

Complete withdrawal of hepatitis B virus prophylaxis after liver transplantation in a recipient at high risk of recurrence.

Tian Shen1, Yufu Ye1, Lei Geng1, Shusen Zheng1.   

Abstract

With the potent nucleos (t) ide analogues developed, necessity of life-long combined prophylaxis against hepatitis B virus (HBV) recurrence after HBV-related liver transplantation has been challenged. But complete withdrawal of HBV prophylaxis has not been previously observed in patients at high recurrence risk who showed active HBV replication before transplant. Herein, we describe a patient with positive HBeAg and HBV-DNA at the time of liver transplantation, who experienced complete HBV prophylaxis withdrawal after 3 years' application of hepatitis B immunoglobulin (HBIG) and entecavir, and showed no HBV recurrence during a long term of follow-up.

Entities:  

Keywords:  Hepatitis B virus; entecavir; hepatitis B immunoglobulin; liver transplantation; prophylaxis; recurrence; withdrawal

Year:  2015        PMID: 26221402      PMCID: PMC4509347     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  8 in total

1.  Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.

Authors:  D J W Wesdorp; M Knoester; A E Braat; M J Coenraad; A C T M Vossen; E C J Claas; B van Hoek
Journal:  J Clin Virol       Date:  2013-07-20       Impact factor: 3.168

2.  Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.

Authors:  Ilaria Lenci; Giuseppe Tisone; Daniele Di Paolo; Fabio Marcuccilli; Laura Tariciotti; Marco Ciotti; Valentina Svicher; Carlo Federico Perno; Mario Angelico
Journal:  J Hepatol       Date:  2011-01-18       Impact factor: 25.083

3.  Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis.

Authors:  Shusen Zheng; Yaomin Chen; Tingbo Liang; Anwei Lu; Weilin Wang; Yan Shen; Min Zhang
Journal:  Liver Transpl       Date:  2006-02       Impact factor: 5.799

4.  A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.

Authors:  Peter W Angus; Scott J Patterson; Simone I Strasser; Geoffrey W McCaughan; Edward Gane
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

5.  Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?

Authors:  Norah Terrault
Journal:  Am J Gastroenterol       Date:  2013-06       Impact factor: 10.864

Review 6.  HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation.

Authors:  Amir Kasraianfard; Kymberly D Watt; Lance Lindberg; Sophoclis Alexopoulos; Nima Rezaei
Journal:  Int Rev Immunol       Date:  2014-06-09       Impact factor: 5.311

7.  Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin.

Authors:  Nam-Joon Yi; Jong Young Choi; Kyung-Suk Suh; Jai Young Cho; Minjung Baik; Geun Hong; Kwang-Woong Lee; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Dong Goo Kim
Journal:  J Gastroenterol       Date:  2013-03-06       Impact factor: 7.527

8.  Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?

Authors:  Akinobu Takaki; Takahito Yagi; Tetsuya Yasunaka; Hiroshi Sadamori; Susumu Shinoura; Yuzo Umeda; Ryuichi Yoshida; Daisuke Sato; Daisuke Nobuoka; Masashi Utsumi; Yuko Yasuda; Eiichi Nakayama; Yasuhiro Miyake; Fusao Ikeda; Hidenori Shiraha; Kazuhiro Nouso; Toshiyoshi Fujiwara; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2013-02-23       Impact factor: 7.527

  8 in total
  1 in total

1.  A model integrating donor gene polymorphisms predicts fibrosis after liver transplantation.

Authors:  Chao Wang; Xueyou Zhang; Qi Ling; Shusen Zheng; Xiao Xu
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.